82 related articles for article (PubMed ID: 25149154)
1. α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Abbas M; Ploch EM; Wehling J; Schipper E; Janciauskiene S; Kreipe HH; Jonigk D
Tumour Biol; 2014 Dec; 35(12):12015-20. PubMed ID: 25149154
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
3. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C; O'Keefe L; Heffron CCBB
Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
[TBL] [Abstract][Full Text] [Related]
4. Rate of Immunohistochemistry Utilization in the Diagnosis of Cutaneous Melanocytic Lesions.
Chen TC; Hitchcock MG
Am J Dermatopathol; 2021 Dec; 43(12):e146-e148. PubMed ID: 33795556
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S).
Wilson BA; Wang H; Nacev BA; Mease RC; Liu JO; Pomper MG; Isaacs WB
Mol Cancer Ther; 2011 May; 10(5):825-38. PubMed ID: 21441411
[TBL] [Abstract][Full Text] [Related]
6. Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.
Cohen PR; Bedikian AY; Kim KB
J Clin Aesthet Dermatol; 2013 May; 6(5):27-37. PubMed ID: 23710269
[TBL] [Abstract][Full Text] [Related]
7. An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
Clarke LE; Flake DD; Busam K; Cockerell C; Helm K; McNiff J; Reed J; Tschen J; Kim J; Barnhill R; Elenitsas R; Prieto VG; Nelson J; Kimbrell H; Kolquist KA; Brown KL; Warf MB; Roa BB; Wenstrup RJ
Cancer; 2017 Feb; 123(4):617-628. PubMed ID: 27768230
[TBL] [Abstract][Full Text] [Related]
8. A study on the AMACR catalysed elimination reaction and its application to inhibitor testing.
Yevglevskis M; Lee GL; Sun J; Zhou S; Sun X; Kociok-Köhn G; James TD; Woodman TJ; Lloyd MD
Org Biomol Chem; 2016 Jan; 14(2):612-622. PubMed ID: 26537174
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of α-methylacyl CoA racemase from Anisakis simplex larvae.
Kim BJ; Kim SM; Cho MK; Yu HS; Lee YS; Cha HJ; Ock M
Korean J Parasitol; 2012 Jun; 50(2):165-71. PubMed ID: 22711931
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity in melanocytic lesions: A potential marker of tumor biology.
Rudolph P; Schubert C; Tamm S; Heidorn K; Hauschild A; Michalska I; Majewski S; Krupp G; Jablonska S; Parwaresch R
Am J Pathol; 2000 Apr; 156(4):1425-32. PubMed ID: 10751366
[TBL] [Abstract][Full Text] [Related]
11. Image and statistical analysis of melanocytic histology.
Miedema J; Marron JS; Niethammer M; Borland D; Woosley J; Coposky J; Wei S; Reisner H; Thomas NE
Histopathology; 2012 Sep; 61(3):436-44. PubMed ID: 22687043
[TBL] [Abstract][Full Text] [Related]
12. Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma.
Moore DA; Saldanha G; Ehdode A; Mughal MZ; Potter L; Dyall L; Pringle JH
J Mol Diagn; 2015 Sep; 17(5):616-22. PubMed ID: 26134170
[TBL] [Abstract][Full Text] [Related]
13. Stem cell spreading dynamics intrinsically differentiate acral melanomas from nevi.
Eshiba S; Namiki T; Mohri Y; Aida T; Serizawa N; Shibata T; Morinaga H; Nanba D; Hiraoka Y; Tanaka K; Miura K; Tanaka M; Uhara H; Yokozeki H; Saida T; Nishimura EK
Cell Rep; 2021 Aug; 36(5):109492. PubMed ID: 34348144
[TBL] [Abstract][Full Text] [Related]
14. HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes?
Campoli M; Fitzpatrick JE; High W; Ferrone S
J Am Acad Dermatol; 2012 Jun; 66(6):911-6, 916.e1-8. PubMed ID: 22445792
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tubulin β-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma.
Katarzyna L; Kyriakos O; Linda V; Ingrid S; Petra W; Karin Ö
Ann Diagn Pathol; 2024 May; 72():152332. PubMed ID: 38776734
[TBL] [Abstract][Full Text] [Related]
16. Imaging Mass Spectrometry-Based Proteomic Analysis to Differentiate Melanocytic Nevi and Malignant Melanoma.
Casadonte R; Kriegsmann M; Kriegsmann K; Hauk I; Meliß RR; Müller CSL; Kriegsmann J
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206844
[TBL] [Abstract][Full Text] [Related]
17. Alpha-methyl CoA racemase (AMACR) reactivity across the spectrum of clear cell renal cell neoplasms.
Rotterova P; Alaghehbandan R; Skopal J; Rogala J; Slisarenko M; Strakova Peterikova A; Michalova K; Montiel DP; Farcas M; Ulamec M; Stransky P; Fiala O; Pitra T; Hora M; Michal M; Pivovarcikova K; Hes O
Ann Diagn Pathol; 2024 Mar; 71():152297. PubMed ID: 38579443
[TBL] [Abstract][Full Text] [Related]
18. Shedding light on PRAME expression in dysplastic nevi: a cohort study.
Innocenti L; Scarpitta R; Corraro S; Ortenzi V; Bonadio AG; Loggini B; De Ieso K; Naccarato AG; Fanelli GN; Scatena C
Virchows Arch; 2023 Dec; ():. PubMed ID: 38112793
[TBL] [Abstract][Full Text] [Related]
19. Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency.
Alsalamah AK; Khan AO
Mol Vis; 2021; 27():396-402. PubMed ID: 34267495
[TBL] [Abstract][Full Text] [Related]
20. Claudin-18 as a Promising Surrogate Marker for Endocervical Gastric-type Carcinoma.
Kiyokawa T; Hoang L; Pesci A; Alvarado-Cabrero I; Oliva E; Park KJ; Soslow RA; Stolnicu S
Am J Surg Pathol; 2022 May; 46(5):628-636. PubMed ID: 34864774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
